Seeking Alpha

Horizon Pharma (HZNP -1.8%) receives a marketing authorization from the UK Medicines and...

Horizon Pharma (HZNP -1.8%) receives a marketing authorization from the UK Medicines and Healthcare products Regulatory Agency for Duexis, for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing upper gastrointestinal ulcers. The authorization stemmed from the favorable recommendation coming out of the Commission on Human Medicines.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs